V H Shah

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Gene transfer of recombinant endothelial nitric oxide synthase to liver in vivo and in vitro
    V Shah
    Gastrointestinal Research Unit and Anesthesia Research Unit, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Physiol Gastrointest Liver Physiol 279:G1023-30. 2000
  2. ncbi Molecular mechanisms of increased intrahepatic resistance in portal hypertension
    Vijay Shah
    Gastrointestinal Research Unit and Advanced Liver Disease Study Group, Mayo Clinic, Rochester, MN, USA
    J Clin Gastroenterol 41:S259-61. 2007
  3. ncbi Nitric oxide in gastrointestinal health and disease
    Vijay Shah
    GI Research Unit, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Gastroenterology 126:903-13. 2004
  4. ncbi Mechanisms of nitric oxide interplay with Rho GTPase family members in modulation of actin membrane dynamics in pericytes and fibroblasts
    June Sung Lee
    GI Research Unit, Al 2 435, Mayo Clinic, 200 First St SW, Rochester, MN 55905
    Am J Pathol 166:1861-70. 2005
  5. ncbi Management of portal hypertension
    Vijay H Shah
    Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Postgrad Med 119:14-8. 2006
  6. ncbi Nitric oxide in liver transplantation: pathobiology and clinical implications
    Vijay Shah
    GI Research Unit and Advanced Liver Disease Study Group, Department of Medicine, Alfred 2 435, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Liver Transpl 9:1-11. 2003
  7. ncbi Cellular and molecular basis of portal hypertension
    V Shah
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Clin Liver Dis 5:629-44. 2001
  8. ncbi Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in rats
    V Shah
    Gastrointestinal Research Unit, Mayo Clinic, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 280:G1209-16. 2001
  9. ncbi Vascular biology and pathobiology of the liver: Report of a single-topic symposium
    Yasuko Iwakiri
    Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
    Hepatology 47:1754-63. 2008
  10. ncbi Focal adhesion assembly in myofibroblasts fosters a microenvironment that promotes tumor growth
    Ningling Kang
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Pathol 177:1888-900. 2010

Research Grants

  1. MULTIDISCIPLINARY TRAINING IN DIGESTIVE DISEASES
    Vijay Shah; Fiscal Year: 2007
  2. Molecular Mechanisms of Portal Hypertension
    Vijay Shah; Fiscal Year: 2007
  3. Molecular Mechanisms of Portal Hypertension
    Vijay Shah; Fiscal Year: 2009
  4. Mechanisms of Nitric Oxide Signaling in Vascular Remodeling
    Vijay H Shah; Fiscal Year: 2010
  5. Molecular Mechanisms of Portal Hypertension
    Vijay H Shah; Fiscal Year: 2010
  6. Failure of FasL Mediated Pathways in Tumor Angiogenesis
    Vijay Shah; Fiscal Year: 2006
  7. Molecular Mechanisms of Portal Hypertension
    Vijay Shah; Fiscal Year: 2006
  8. Inhibition of TNF in Patients with Alcoholic Hepatitis
    Vijay Shah; Fiscal Year: 2005
  9. REG OF NITRIC OXIDE PRODUCT IN THE HEPATIC CIRCULATION
    Vijay Shah; Fiscal Year: 2002
  10. Endothelial Nitric Oxide Synthase & Portal Hypertension
    Vijay Shah; Fiscal Year: 2002

Collaborators

Detail Information

Publications43

  1. ncbi Gene transfer of recombinant endothelial nitric oxide synthase to liver in vivo and in vitro
    V Shah
    Gastrointestinal Research Unit and Anesthesia Research Unit, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Physiol Gastrointest Liver Physiol 279:G1023-30. 2000
    ..These events were associated with increased ionomycin-stimulated NO release. In summary, this is the first study to demonstrate successful delivery of the recombinant eNOS gene to liver in vivo and in vitro with ensuing NO production...
  2. ncbi Molecular mechanisms of increased intrahepatic resistance in portal hypertension
    Vijay Shah
    Gastrointestinal Research Unit and Advanced Liver Disease Study Group, Mayo Clinic, Rochester, MN, USA
    J Clin Gastroenterol 41:S259-61. 2007
    ..This review will focus on these processes within the intrahepatic circulation, a circulatory bed whose study, that Dr Roberto Groszmann has pioneered...
  3. ncbi Nitric oxide in gastrointestinal health and disease
    Vijay Shah
    GI Research Unit, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Gastroenterology 126:903-13. 2004
    ....
  4. ncbi Mechanisms of nitric oxide interplay with Rho GTPase family members in modulation of actin membrane dynamics in pericytes and fibroblasts
    June Sung Lee
    GI Research Unit, Al 2 435, Mayo Clinic, 200 First St SW, Rochester, MN 55905
    Am J Pathol 166:1861-70. 2005
    ..In conclusion, these studies identify novel crosstalk between small GTPases, cytoskeletal structures, and NO in pericyte-specific pathways, providing counterbalances in the chemotactic responses to growth factors...
  5. ncbi Management of portal hypertension
    Vijay H Shah
    Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Postgrad Med 119:14-8. 2006
    ..Because the prognosis for patients with hepatic encephalopathy is generally poor, orthotopic liver transplantation should be considered...
  6. ncbi Nitric oxide in liver transplantation: pathobiology and clinical implications
    Vijay Shah
    GI Research Unit and Advanced Liver Disease Study Group, Department of Medicine, Alfred 2 435, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Liver Transpl 9:1-11. 2003
    ..This review article focuses on new advances relating to the role of nitric oxide in these syndromes with an emphasis on pathobiology and potential clinical implications...
  7. ncbi Cellular and molecular basis of portal hypertension
    V Shah
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Clin Liver Dis 5:629-44. 2001
    ....
  8. ncbi Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in rats
    V Shah
    Gastrointestinal Research Unit, Mayo Clinic, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 280:G1209-16. 2001
    ..We conclude that, in cholestatic portal hypertension, caveolin may negatively regulate NOS activity in a manner that is reversible by excess calmodulin...
  9. ncbi Vascular biology and pathobiology of the liver: Report of a single-topic symposium
    Yasuko Iwakiri
    Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
    Hepatology 47:1754-63. 2008
    ..Finally, clinical and translational sessions focused on emerging therapies and technologies to treat vascular diseases of the liver...
  10. ncbi Focal adhesion assembly in myofibroblasts fosters a microenvironment that promotes tumor growth
    Ningling Kang
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Pathol 177:1888-900. 2010
    ..Taken together, our results identify Ena/VASP as a significant modifier of tumor growth through regulation of FA dynamics and ensuing pericyte/myofibroblast function within the tumor microenvironment...
  11. ncbi KLF11-mediated repression antagonizes Sp1/sterol-responsive element-binding protein-induced transcriptional activation of caveolin-1 in response to cholesterol signaling
    Sheng Cao
    Gastroenterology Research Unit and Tumor Biology Program, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Biol Chem 280:1901-10. 2005
    ....
  12. ncbi Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function
    David Semela
    GI Research Unit Fitterman Center for Digestive Disease, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterology 135:671-9. 2008
    ....
  13. ncbi Inhibition of GTP-dependent vesicle trafficking impairs internalization of plasmalemmal eNOS and cellular nitric oxide production
    Suvro Chatterjee
    GI Research Unit, Department of Physiology, and Tumor Biology Program, Mayo Clinic, Rochester, MN 55905, USA
    J Cell Sci 116:3645-55. 2003
    ....
  14. ncbi Centrilobular necrosis after orthotopic liver transplantation: association with acute cellular rejection and impact on outcome
    Ziad Hassoun
    Advanced Liver Disease Study Group, Mayo Clinic, Rochester, MN, USA
    Liver Transpl 10:480-7. 2004
    ..In conclusion, the presence of cholestasis and lobular inflammation on biopsies with CN appeared helpful in predicting its association with ACR...
  15. ncbi Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling
    Resham Bhattacharya
    Department of Biochemistry and Molecular Biology, Mayo Clinic Cancer Center, Rochester, Minnesota 55905, USA
    FASEB J 19:1692-4. 2005
    ..Taken together, our findings suggest that dynamin-2 regulates KDR expression and function and hence plays an important role in VPF/VEGF mediated angiogenesis...
  16. ncbi Characterization of the CXCR4 signaling in pancreatic cancer cells
    Daniel D Billadeau
    Oncology Research Department, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Int J Gastrointest Cancer 37:110-9. 2006
    ....
  17. ncbi Inhibition of VEGF- and NO-dependent angiogenesis does not impair liver regeneration
    U Shergill
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Physiol Regul Integr Comp Physiol 298:R1279-87. 2010
    ..In summary, inhibition of VEGF- and NO-dependent angiogenesis does not impair liver regeneration, indicating signaling redundancies that allow liver regeneration to continue in the absence of this canonical vascular pathway...
  18. ncbi Nitric oxide promotes endothelial cell survival signaling through S-nitrosylation and activation of dynamin-2
    Ningling Kang Decker
    GI Research Unit, Department of Physiology and Tumor Biology Program, Mayo Clinic, Rochester, MN 55903, USA
    J Cell Sci 120:492-501. 2007
    ....
  19. ncbi Serotonin transporter polymorphisms in patients with portopulmonary hypertension
    Kari E Roberts
    Department of Medicine, Tufts Medical Center, Boston, MA, USA
    Chest 135:1470-5. 2009
    ..We hypothesized that the long allele or other polymorphisms in SERT would be associated with an increased risk of portopulmonary hypertension (PPHTN) in patients with advanced liver disease...
  20. ncbi Diverse origin and function of cells with endothelial phenotype obtained from adult human blood
    Rajiv Gulati
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic College of Medicine, 200 First St SW, Rochester, Minn 55905, USA
    Circ Res 93:1023-5. 2003
    ....
  21. ncbi The proline-rich domain of dynamin-2 is responsible for dynamin-dependent in vitro potentiation of endothelial nitric-oxide synthase activity via selective effects on reductase domain function
    Sheng Cao
    Gastrointestinal Research Unit and Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Biol Chem 278:5894-901. 2003
    ....
  22. ncbi Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis
    Brianna E Vaa
    Mayo Medical School, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 86:37-42. 2011
    ....
  23. ncbi Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease
    Kari E Roberts
    Department of Medicine, Tufts Medical Center, Boston, MA 02111, USA
    Am J Respir Crit Care Med 179:835-42. 2009
    ..Portopulmonary hypertension (PPHTN) occurs in 6% of liver transplant candidates. The pathogenesis of this complication of portal hypertension is poorly understood...
  24. ncbi Risk factors and impact of chronic obstructive pulmonary disease in candidates for liver transplantation
    Debbie Rybak
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Liver Transpl 14:1357-65. 2008
    ..Older age and smoking are significant risk factors of COPD, which has adverse consequences on functional status and quality of life in these patients...
  25. ncbi Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease
    Kari E Roberts
    Department of Medicine, Tufts Medical Center, Boston, Massachusetts 02111, USA
    Gastroenterology 139:130-9.e24. 2010
    ..We investigated genetic risk factors for HPS in patients with advanced liver disease...
  26. ncbi Interplay of tumor microenvironment cell types with parenchymal cells in pancreatic cancer development and therapeutic implications
    Praveen Guturu
    Gastroenterology Research Unit and Fiterman Center for Digestive Diseases, Mayo Clinic Rochester MN, 200 First Street SW, Rochester, MN 55905, USA
    J Gastrointest Cancer 40:1-9. 2009
    ..The process of "induction," namely, the formation of a tissue by the functional interaction between the epithelial layer and the stroma, is key for the development of many organs, in particular to the pancreas...
  27. ncbi The Budd-Chiari syndrome
    K V Narayanan Menon
    Advanced Liver Disease Study Group, Division of Gastroenterology and Hepatology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    N Engl J Med 350:578-85. 2004
  28. ncbi Ephrin B2/EphB4 pathway in hepatic stellate cells stimulates Erk-dependent VEGF production and sinusoidal endothelial cell recruitment
    Amitava Das
    Gastroenterology Research Unit, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 298:G908-15. 2010
    ..These studies identify EphrinB2 or EphB4 as a key intermediary that links HSC signal transduction pathways with angiogenesis and sinusoidal remodeling...
  29. ncbi Leptin induces phagocytosis of apoptotic bodies by hepatic stellate cells via a Rho guanosine triphosphatase-dependent mechanism
    Joy X Jiang
    Department of Internal Medicine, Division of Gastroenterology and Hepatology, UC Davis Medical Center, Sacramento, CA 95817, USA
    Hepatology 48:1497-505. 2008
    ..Leptin-mediated phagocytic activity of stellate cells therefore could be an important mechanism responsible for progression of fibrosis in non-alcoholic steatohepatitis...
  30. ncbi Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates
    Michael B Fallon
    Department of Medicine, University of Alabama, Birmingham, Alabama 35294 0005, USA
    Gastroenterology 135:1168-75. 2008
    ..We assessed the impact of HPS in patients evaluated for liver transplantation...
  31. ncbi Disruption of an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migration
    Amitava Das
    Gastroenterology Research Unit, Department of Physiology and Cancer Cell Biology Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Biol Chem 281:39105-13. 2006
    ..Thus, together, these studies identify a mechanism for antagonizing Sp/KLF protein repression function via SHP, with this process regulating endothelial cell motility...
  32. ncbi Nitric oxide regulates tumor cell cross-talk with stromal cells in the tumor microenvironment of the liver
    Ningling Kang Decker
    Department of Physiology, Mayo Clinic Rochester, MN 55905, USA
    Am J Pathol 173:1002-12. 2008
    ..Thus, a NO gradient within the tumor microenvironment influences tumor progression through orchestrated molecular interactions between tumor cells and stroma...
  33. ncbi Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis
    Daniel A Langer
    Gastroenterology Research Unit, Department of Physiology and Tumor Biology Program, Al 2-435, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Hepatol 44:209-16. 2006
  34. ncbi Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte?
    June Sung Lee
    Department of Internal Medicine, Inje University Ilsanpaik Hospital, Gyeonggi-do, South Korea
    Hepatology 45:817-25. 2007
  35. ncbi Defects in cGMP-PKG pathway contribute to impaired NO-dependent responses in hepatic stellate cells upon activation
    Roman E Perri
    Gastroenterology Research Unit, Department of Physiology, and Tumor Biology Program, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 290:G535-42. 2006
    ..Activating targets downstream from NO-cGMP in activated HSC may represent a novel therapeutic target for portal hypertension...
  36. ncbi Carbon monoxide activates human intestinal smooth muscle L-type Ca2+ channels through a nitric oxide-dependent mechanism
    Inja Lim
    Enteric Neuroscience Program, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Am J Physiol Gastrointest Liver Physiol 288:G7-14. 2005
    ..CO-induced NO production may explain the apparent discrepancy between the low affinity of guanylyl cyclase for CO and the robust cGMP production evoked by CO...
  37. ncbi Inhibition of ATP binding to the carboxyl terminus of Kir6.2 by epoxyeicosatrienoic acids
    Xiao Li Wang
    Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Biochim Biophys Acta 1761:1041-9. 2006
    ..These findings suggest that the epoxide group in EETs is important for modulation of ATP binding to Kir6.2. We conclude that EETs bind to the C-terminus of K(ATP) channels, inhibiting binding of ATP to the channel...
  38. ncbi A gas, an amino acid, and an imposter: the story of nitric oxide, L-arginine, and ADMA in portal hypertension
    Daniel A Langer
    Hepatology 42:1255-7. 2005
  39. ncbi Proteasome inhibition induces hepatic stellate cell apoptosis
    Akira Anan
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 43:335-44. 2006
    ..In conclusion, proteasome inhibition is a potential therapeutic strategy for inducing HSC apoptosis and inhibiting liver fibrogenesis...
  40. ncbi Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species
    Daniel A Langer
    Gastrointestinal Research Unit and Fiterman Center for Digestive Disease, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 47:1983-93. 2008
    ..CONCLUSION: We postulate that NO-dependent apoptosis of HSCs may maintain sinusoidal homeostasis, and may represent an additional beneficial effect of NO donors for therapy of portal hypertension...
  41. ncbi Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo
    Eugenia Trushina
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
    Hum Mol Genet 15:3578-91. 2006
    ..These data provide the first direct link between mhtt and caveolar-related endocytosis and also suggest a possible mechanism for HD neurotoxicity where cholesterol homeostasis is perturbed...
  42. ncbi Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking
    Yasuko Iwakiri
    Section of Digestive Diseases, Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510, USA
    Proc Natl Acad Sci U S A 103:19777-82. 2006
    ..These data indicate that local NOS action generates organelle-specific protein S-nitrosylation reactions that can regulate intracellular transport processes...
  43. ncbi Caveolae targeting and regulation of large conductance Ca(2+)-activated K+ channels in vascular endothelial cells
    Xiao-Li Wang
    Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Biol Chem 280:11656-64. 2005
    ..These novel findings may have important implications for the role of BK channels in the regulation of endothelial function...

Research Grants25

  1. MULTIDISCIPLINARY TRAINING IN DIGESTIVE DISEASES
    Vijay Shah; Fiscal Year: 2007
    ..This well established but dynamic training program continues to expand and exploit new training opportunities, and remains highly successful in achieving its goal of training individuals for academic careers in enteric sciences. ..
  2. Molecular Mechanisms of Portal Hypertension
    Vijay Shah; Fiscal Year: 2007
    ..abstract_text> ..
  3. Molecular Mechanisms of Portal Hypertension
    Vijay Shah; Fiscal Year: 2009
    ....
  4. Mechanisms of Nitric Oxide Signaling in Vascular Remodeling
    Vijay H Shah; Fiscal Year: 2010
    ..Thus, this work has physiologic, pathobiologic, and therapeutic importance. ..
  5. Molecular Mechanisms of Portal Hypertension
    Vijay H Shah; Fiscal Year: 2010
    ....
  6. Failure of FasL Mediated Pathways in Tumor Angiogenesis
    Vijay Shah; Fiscal Year: 2006
    ..These insights may lead to novel and effective therapeutic strategies that target this pathway to prevent angiogenesis, and thereby prevent colorectal tumor development growth and spread. ..
  7. Molecular Mechanisms of Portal Hypertension
    Vijay Shah; Fiscal Year: 2006
    ....
  8. Inhibition of TNF in Patients with Alcoholic Hepatitis
    Vijay Shah; Fiscal Year: 2005
    ..abstract_text> ..
  9. REG OF NITRIC OXIDE PRODUCT IN THE HEPATIC CIRCULATION
    Vijay Shah; Fiscal Year: 2002
    ..Defining the mechanisms that regulate nitric oxide production in SEC may lead to therapeutic options whereby NO activity may be pharmacologically or genetically modulated and benefit patients with cirrhosis and portal hypertension. ..
  10. Endothelial Nitric Oxide Synthase & Portal Hypertension
    Vijay Shah; Fiscal Year: 2002
    ..abstract_text> ..
  11. Molecular Mechanisms of Portal Hypertension
    Vijay Shah; Fiscal Year: 2009
    ....